Bristol-Myers Squibb (France)

Quality of life and care experience in durable responders to immune checkpoint inhibitors for advanced or metastatic NSCLC or melanoma

Background Immune checkpoint inhibitors (ICIs) have transformed outcomes for advanced/metastatic melanoma and non-small-cell lung cancer (NSCLC), allowing for a growing population of ICI durable responders (ICI-DR). Despite improved survival, ICI-DR patients may face persistent h...

Real-World Use of Adjuvant Nivolumab for Resected Stage III–IV Melanoma: 2-Year Analysis of AdjuMel

Following the positive findings of the phase 3 CheckMate 238 trial, adjuvant nivolumab has become a standard therapy in patients with completely resected stage III–IV melanoma. The prospective, ongoing AdjuMel study is evaluating the real-world use, effectiveness, and safety of a...